Where is fgf23 produced

Content on WhatAnswers is provided "as is" for informational purposes. While we strive for accuracy, we make no guarantees. Content is AI-assisted and should not be used as professional advice.

Last updated: April 8, 2026

Quick Answer: Fibroblast growth factor 23 (FGF23) is primarily produced by osteocytes and osteoblasts in bone tissue, specifically within the mineralized bone matrix. This hormone plays a crucial role in phosphate homeostasis, with abnormal levels linked to disorders like X-linked hypophosphatemia (XLH) and chronic kidney disease-mineral and bone disorder (CKD-MBD).

Key Facts

FGF23 is primarily produced by osteocytes and osteoblasts in bone tissue
FGF23 levels typically range from 10-50 pg/mL in healthy individuals
FGF23 was first identified in 2000 by researchers studying autosomal dominant hypophosphatemic rickets
FGF23 production increases up to 100-fold in conditions like X-linked hypophosphatemia
FGF23 has a half-life of approximately 46-58 minutes in circulation

Overview

Fibroblast growth factor 23 (FGF23) is a key hormonal regulator of phosphate and vitamin D metabolism that was first identified in 2000. This 251-amino acid protein belongs to the fibroblast growth factor family and functions as an endocrine hormone, unlike most FGFs that act locally. The discovery of FGF23 revolutionized our understanding of phosphate homeostasis and bone-mineral metabolism.

Historically, researchers studying rare bone disorders like autosomal dominant hypophosphatemic rickets (ADHR) identified FGF23 as the causative factor. Subsequent research revealed its broader significance in common conditions including chronic kidney disease and osteoporosis. Today, FGF23 is recognized as a central player in the bone-kidney-parathyroid axis that maintains mineral balance throughout the body.

How It Works

FGF23 production and function involve complex regulatory mechanisms that maintain phosphate balance.

Primary Production Sites: FGF23 is predominantly synthesized by osteocytes and osteoblasts within bone tissue. These specialized bone cells produce FGF23 in response to various stimuli including elevated serum phosphate levels, increased 1,25-dihydroxyvitamin D, and parathyroid hormone (PTH). Osteocytes, which comprise 90-95% of all bone cells, are particularly important FGF23 producers.
Regulatory Mechanisms: FGF23 production is tightly regulated through multiple pathways. Phosphate intake directly stimulates FGF23 synthesis, with high-phosphate diets increasing FGF23 levels by 30-50% within hours. Vitamin D metabolites also regulate FGF23, with 1,25-dihydroxyvitamin D increasing FGF23 expression through vitamin D response elements in the FGF23 gene promoter region.
Processing and Secretion: After synthesis, FGF23 undergoes specific processing before secretion. The protein is cleaved between residues 179 and 180 by proprotein convertases, producing biologically active fragments. Intact FGF23 (iFGF23) represents the active hormone, while C-terminal fragments may have different biological activities. Under normal conditions, approximately 50-70% of circulating FGF23 exists in the intact form.
Target Tissues and Effects: FGF23 primarily targets the kidneys through FGF receptors and klotho co-receptor. In renal proximal tubules, FGF23 reduces phosphate reabsorption by downregulating sodium-phosphate cotransporters (NaPi-2a and NaPi-2c). It also suppresses 1α-hydroxylase activity, decreasing active vitamin D production by 40-60%, while stimulating 24-hydroxylase to enhance vitamin D catabolism.

Key Comparisons

Feature	FGF23	Parathyroid Hormone (PTH)
Primary Production Site	Osteocytes/Osteoblasts in bone	Chief cells in parathyroid glands
Main Regulatory Function	Phosphate homeostasis	Calcium homeostasis
Effect on Vitamin D	Decreases 1,25(OH)2D production	Increases 1,25(OH)2D production
Response to Phosphate	Increases with high phosphate	Minimal direct response
Half-life in Circulation	46-58 minutes	2-4 minutes
Associated Disorders	XLH, CKD-MBD	Hyperparathyroidism, Osteoporosis

Why It Matters

Clinical Diagnostics: FGF23 measurements have become essential for diagnosing phosphate-wasting disorders. In X-linked hypophosphatemia (XLH), FGF23 levels can be 10-100 times higher than normal ranges (10-50 pg/mL). Accurate measurement helps distinguish between FGF23-mediated and non-FGF23-mediated hypophosphatemia, guiding appropriate treatment decisions.
Therapeutic Applications: Anti-FGF23 antibodies like burosumab have revolutionized treatment for XLH, improving phosphate levels and reducing rickets severity by 70-80% in clinical trials. Understanding FGF23 production has enabled targeted therapies that specifically address the underlying hormonal imbalance rather than just symptom management.
Chronic Disease Management: In chronic kidney disease (CKD), elevated FGF23 levels predict cardiovascular events and mortality. Patients with CKD stage 3-4 have FGF23 levels 2-5 times higher than healthy individuals, with each doubling of FGF23 associated with a 30-50% increased risk of cardiovascular events. Monitoring FGF23 helps identify high-risk patients for early intervention.

As research continues, our understanding of FGF23 production and function expands beyond traditional mineral metabolism. Emerging evidence suggests FGF23 may influence immune function, cardiovascular health, and aging processes. Future research will likely uncover additional production sites and regulatory mechanisms, potentially leading to novel therapeutic approaches for a wide range of disorders affecting millions worldwide. The ongoing study of FGF23 represents a frontier in endocrine research with implications for bone health, kidney function, and systemic metabolism.